In the second paragraph of the Introduction section, the last portion of the first sentence states: "… and approved for use for the treatment of osteoporosis in Japan [11] ." This was inadequately referenced, and should be "approved for use for the treatment of osteoporosis in Japan [11, [17] [18] [19] ." In the fourth paragraph of the Discussion section, the first portion of the first sentence states: "While many reports have indicated the bone density-increasing effects of switching to daily minodronate from other BPs [11, [17] [18] [19] , …" This was incorrectly referenced, and should be "While many reports have indicated the bone density-increasing effects of switching to daily minodronate from other BPs [23] [24] [25] , …" In the fifth paragraph of the Discussion section, the first portion of the first sentence states: "While daily minodronate has been reported to alleviate low back pain [19] , …". Additionally, in the sixth paragraph of the Discussion section, the first sentence states: "We have already reported that daily minodronate treatment induced fewer GI symptoms in comparison with weekly alendronate treatment [19] ." The reference number [19] is incorrect and should be [18] in both cases.
An inappropriate publication was cited as reference 21. The correct reference is: 21. Nozaki K, Kakimoto S, Kimoto A, Yoshino T, Sato Y, Yoshida A, Nakamura T (2011) Investigation into the analgesic effects of minodronic acid hydrate via P2X 2/3 receptor (in Japanese). Shinyaku To Rinsho (J New Rem Clin) 60 (9):1766-1774
The following three publications should have been included in the References section. 
